Navigation Links
Assurex Health Appoints Veteran P&G Consumer Products Executive Virginia Coleman Drosos President to Lead Personalized Medicine Growth
Date:9/9/2013

MASON, Ohio, Sept. 9, 2013 /PRNewswire/ -- Assurex Health, a personalized medicine company specializing in pharmacogenomics for neuropsychiatric and other disorders, today announced that Procter & Gamble veteran Virginia "Gina" Coleman Drosos has joined its leadership team in the role of President.

(Photo: http://photos.prnewswire.com/prnh/20130909/CL75940)
(Logo: http://photos.prnewswire.com/prnh/20130910/CL75944LOGO)  

Drosos joins Assurex Health with more than 25 years of global business leadership, innovation, operations and consumer marketing expertise. During her 25 year career at The Procter & Gamble Company (PG), Gina held positions of increasing responsibility in the United States and internationally delivering strong proven results.  She most recently served P&G as Group President for Global Beauty Care, a $6 billion global business unit with over 6,000 employees in 120 countries. 

"Gina brings extensive leadership and strong results on global consumer-driven businesses," said James S. Burns, CEO of Assurex Health.  "I'm particularly excited about Gina joining the team because health care is rapidly moving into an era of patient-empowerment, leading a shift to consumer-enabled personalized medicine.  In bringing neuropsychiatric pharmacogenomics to a market of 40+ million patients in the U.S. alone, Assurex will benefit from Gina's experience in creating awareness and cultivating a huge base of patients/consumers/caregivers, 80% of whom are women as the primary medical decision maker."

Assurex Health's pharmacogenomic technology is a breakthrough in personalized medicine.  Based on each patient's personal genetic profile, GeneSight tests help clinicians determine the right treatment medications for patients with depression, ADHD, chronic pain and other neuropsychiatric disorders. "Eliminating today's typical trial and error process for selecting medications can help people reclaim their lives and reduces healthcare costs," said Drosos.  "I look forward to applying my experience leading in the consumer space to help make personalized medicine a standard of care in the industry.  With exciting new innovations in the pipeline and our technology-information-consumer platform, I'm confident Assurex will help more physicians and practitioners determine the best treatment options and lead the movement toward consumer-enabled personalized medicine."

Drosos also serves on the Board of Directors for several major corporations including Signet Jewelers Ltd. (SIG) and American Financial Group (AFG).  Drosos earned a Bachelor of Business Administration in Finance from the University of Georgia, a Master of Business Administration from The Wharton School, University of Pennsylvania, and was recognized as one of Fortune's 50 Most Powerful Women in Business in 2010 and 2011.

About Assurex Health
Assurex Health is a personalized medicine company that specializes in pharmacogenomics and is dedicated to helping physicians determine the right medication for individual patients suffering from neuropsychiatric and other disorders. The company was founded in 2006 to commercialize industry-leading personalized medicine technology developed by Assurex Health based on technology licensed from Mayo Clinic and Cincinnati Children's Hospital Medical Center who remain technology collaborators.  For more information about Assurex Health, visit www.assurexhealth.com.

About GeneSight
GeneSight is a laboratory developed pharmacogenomic test that uses cutting edge technology to measure and analyze clinically important genomic variants in the treatment of psychiatric disorders and pain. The results of the GeneSight report can help a clinician understand the way a patient's unique genomic makeup may affect the effectiveness of certain psychiatric medications. The analysis is based on pharmacogenomics, the study of genomic factors that influence an individual's response to drug treatments, FDA approved manufacturer's drug labels, peer-reviewed scientific and clinical publications, and proven drug pharmacology. Quick turnaround time, combined with a customized report of the patient's genomic makeup, clinical experience and other factors can help a physician make better personalized drug treatment choices for each patient.


'/>"/>
SOURCE Assurex Health
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Assurex Health Appoints Chief Financial Officer and Payer Market Executive to Manage Rapid Growth in Personalized Medicine
2. Omeros to Present at the Stifel Healthcare Conference 2013
3. FDA approves drug tested by Scottsdale Healthcare and TGen
4. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference
5. Quest Diagnostics to Speak at the Morgan Stanley Global Healthcare Conference
6. Shire to Present at the Morgan Stanley Global Healthcare Conference
7. Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch Global Healthcare Conference
8. Sorrento Therapeutics to Present at Two Healthcare Conferences
9. Rigel to Present at Stifel Healthcare Conference
10. BioDelivery Sciences to Present at the Stifel Nicolaus 2013 Healthcare Conference
11. Lexicon To Present At The Stifel Nicolaus Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017  Ethicon* today announced ... Inc., a privately held medical device company that ... for the surgical treatment of Gastroesophageal Reflux Disease ... of expanding its portfolio of minimally invasive options ... conditions. Financial terms of the transaction have not ...
(Date:3/23/2017)... , March 23, 2017  Additive Orthopaedics, ... announced that it has kicked off a multi-centered ... 3D printed bone segments. According to ... unique variable honeycomb lattice structures have already shown ... compared to current allograft wedges from which we ...
(Date:3/23/2017)... 23, 2017 Ascendis Pharma A/S (Nasdaq: ASND), ... to address significant unmet medical needs in rare diseases, ... call and webcast on Monday, April 3 during ENDO ... Orlando, Florida , to discuss new ... Growth Hormone, TransCon PTH and TransCon CNP). ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... Benefits ... an innovative mobile app and centralized benefits dashboard solving one of the top ... from multiple locations. For the first time, employees can access up-to-date information and ...
(Date:3/23/2017)... ... March 23, 2017 , ... Michael Lanteri ... the greater Fort Collins area, has unveiled a collaboration with nonprofit Big Bones ... Donations to this worthy cause may now be made at http://bigbonescaninerescue.com/ . ...
(Date:3/23/2017)... Fla. (PRWEB) , ... March 23, 2017 , ... ... transforming healthcare for seniors, today announced rapid completion of the strategic executive team ... announce several notable additions to the ChenMed executive team,” says Christopher Chen, MD, ...
(Date:3/23/2017)... ... March 23, 2017 , ... Inflow IQ & Inflownomics ... serious so build on a solid foundation. As experts in dangerous situations the ... that is coming soon. Inflownomics deliver ripe, fresh, clean & refreshing knowledge systems that ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... awarded Task Force Dagger Foundation the US Special Operations Command’s Patriot Award. The ... presentation, General Thomas thanked Task Force Dagger Foundation for its significant and enduring ...
Breaking Medicine News(10 mins):